About Organon & Co.
https://www.organon.comOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
CEO
Kevin Ali
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 229
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:35.93M
Value:$309.34M
BLACKROCK INC.
Shares:32.58M
Value:$280.51M
BLACKROCK, INC.
Shares:30.86M
Value:$265.69M
Summary
Showing Top 3 of 824
About Organon & Co.
https://www.organon.comOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.6B ▲ | $499M ▼ | $160M ▲ | 9.99% ▲ | $0.62 ▲ | $460M ▲ |
| Q2-2025 | $1.59B ▲ | $548M ▲ | $145M ▲ | 9.1% ▲ | $0.56 ▲ | $449M ▲ |
| Q1-2025 | $1.51B ▼ | $516M ▼ | $87M ▼ | 5.75% ▼ | $0.34 ▼ | $325M ▼ |
| Q4-2024 | $1.59B ▲ | $600M ▲ | $109M ▼ | 6.85% ▼ | $0.42 ▼ | $341M ▼ |
| Q3-2024 | $1.58B | $533M | $359M | 22.69% | $1.39 | $402M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $672M ▲ | $13.55B ▲ | $12.65B ▼ | $906M ▲ |
| Q2-2025 | $599M ▲ | $13.5B ▲ | $12.77B ▲ | $733M ▲ |
| Q1-2025 | $547M ▼ | $13.16B ▲ | $12.61B ▼ | $542M ▲ |
| Q4-2024 | $675M ▼ | $13.1B ▲ | $12.63B ▲ | $472M ▼ |
| Q3-2024 | $763M | $12.75B | $12.26B | $493M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $160M ▲ | $264M ▲ | $-115M ▼ | $-76M ▲ | $73M ▲ | $149M ▼ |
| Q2-2025 | $145M ▲ | $220M ▲ | $-38M ▲ | $-223M ▼ | $52M ▲ | $181M ▲ |
| Q1-2025 | $87M ▼ | $75M ▼ | $-172M ▲ | $-75M ▲ | $-128M ▼ | $-22M ▼ |
| Q4-2024 | $109M ▼ | $390M ▲ | $-296M ▼ | $-82M ▼ | $-88M ▼ | $258M ▲ |
| Q3-2024 | $359M | $141M | $-75M | $-78M | $59M | $65M |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Asia Pacific And Japan | $500.00M ▲ | $250.00M ▼ | $250.00M ▲ | $250.00M ▲ |
 CHINA | $430.00M ▲ | $200.00M ▼ | $200.00M ▲ | $220.00M ▲ |
 Europe And Canada | $1.33Bn ▲ | $380.00M ▼ | $420.00M ▲ | $420.00M ▲ |
 Latin America Middle East Russia And Africa | $790.00M ▲ | $240.00M ▼ | $280.00M ▲ | $290.00M ▲ |
 Other Countries | $70.00M ▲ | $30.00M ▼ | $20.00M ▼ | $20.00M ▲ |
 UNITED STATES | $800.00M ▲ | $410.00M ▼ | $410.00M ▲ | $410.00M ▲ |
CEO
Kevin Ali
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 229
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:35.93M
Value:$309.34M
BLACKROCK INC.
Shares:32.58M
Value:$280.51M
BLACKROCK, INC.
Shares:30.86M
Value:$265.69M
Summary
Showing Top 3 of 824